Table 6. Results for the efficacy and safety-related endpoints from the network meta-analysis.

Endpoint	Patient subgroup	Model (RE/FE)	Pairwise comparison	OR (CrI)
Clinical Treatment Success	Adult	RE	DAL vs VAN	0.99 (0.68; 1.51)
			DAL vs LZD	0.69 (0.41; 1.00)
			DAL vs DAP	1.05 (0.61; 2.10)
			DAL vs TIG	1.18 (0.71; 2.10)
	Mixed Population	RE	DAL vs VAN	0.96 (0.69; 1.35)
			DAL vs LZD	0.73 (0.50; 1.02)
			DAL vs DAP	1.00 (0.63; 1.76)
			DAL vs TIG	1.14 (0.72; 1.83)
			DAL vs TEI	1.67 (0.44; 7.37)
Microbiological success	Adult	RE	DAL vs VAN	1.31 (0.40; 4.93)
			DAL vs LZD	0.53 (0.11; 1.85)
			DAL vs DAP	1.85 (0.32; 12.72)
			DAL vs TIG	2.29 (0.44; 14.36)
	Mixed Population	RE	DAL vs VAN	1.21 (0.41; 4.01)
			DAL vs LZD	0.61 (0.16; 1.87)
			DAL vs DAP	1.71 (0.33; 10.11)
			DAL vs TIG	2.10 (0.47; 11.32)
Discontinuation due to AEs/SAEs	Adult	FE	DAL vs VAN	1.08 (0.59; 1.98)
			DAL vs LZD	1.24 (0.68; 2.30)
			DAL vs DAP	1.28 (0.53; 3.09)
			DAL vs TIG	1.43 (0.65; 3.23)
Patients experiencing AEs	Adult	FE	DAL vs VAN	0.85 (0.70; 1.03)
			DAL vs LZD	0.78 (0.62; 0.98)
			DAL vs DAP	1.05 (0.76; 1.46)
			DAL vs TIG	0.78 (0.59; 1.02)
Patients experiencing SAEs	Adult	FE	DAL vs VAN	0.54 (0.30; 0.96)
			DAL vs LZD	0.99 (0.61; 1.66)
			DAL vs DAP	0.48 (0.24; 0.95)
			DAL vs TIG	0.58 (0.25; 1.35)
All-cause mortality	Adult	FE	DAL vs VAN	0.26 (0.05; 0.93)
			DAL vs LZD	0.20 (0.04; 0.77)
			DAL vs DAP	0.34 (0.05; 1.71)
			DAL vs TIG	0.06 (0.00; 0.44)

Abbreviations: AE: adverse event; CrI: credible interval; DAL: dalbavancin; DAP: daptomycin; FE: Fixed Effect; LZD: linezolid; RE: random effect; SAE: serious adverse event; TEI: teicoplanin; TIG: tigecycline; VAN: vancomycin.

In bold, statistically significant.